Poviztra 2.4mg FlexTouch is used to:

• Manage obesity: It is used along with a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI of 30 kg/m² or greater.

• Manage overweight with weight-related health conditions: It may be used in adults with a BMI of 27 kg/m² or greater who have at least one weight-related condition such as hypertension, type 2 diabetes mellitus or dyslipidaemia.

• Reduce cardiovascular risk: It is indicated to reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal heart attack and non-fatal stroke, in adults with established cardiovascular disease who have obesity or overweight.

Poviztra 2.4mg FlexTouch contains Semaglutide, which activates GLP-1 receptors involved in appetite and food intake regulation.

It increases feelings of fullness, reduces hunger and can decrease food intake. Semaglutide also slows stomach emptying, which can contribute to reduced appetite and support weight management when combined with a reduced-calorie diet and physical activity.

Tell your doctor about all prescription medicines, over-the-counter medicines, vitamins and herbal supplements you take.

• Insulin or sulfonylureas: Using Semaglutide with these medicines may increase the risk of low blood sugar.

• Other GLP-1 medicines or Semaglutide-containing products: Do not use Poviztra with another Semaglutide-containing medicine or another GLP-1 receptor agonist unless specifically prescribed.

• Oral medicines: Semaglutide can delay stomach emptying and may affect the absorption of some medicines taken by mouth. Tell your doctor about medicines that require careful monitoring.

• Store Poviztra 2.4mg FlexTouch in a refrigerator at 2°C to 8°C.

• Do not freeze the pen or use it if it has been frozen.

• Keep the pen protected from light.

• Keep it out of the sight and reach of children.

• Follow the product packaging instructions for storage after first use.

Poviztra 2.4mg FlexTouch is injected once a week under the skin of the abdomen, thigh or upper arm.

The 2.4mg strength is the usual maintenance dose and is reached gradually after treatment with lower strengths. Do not increase to 2.4mg unless your doctor has advised you to do so.

Use the FlexTouch pen only after you have been shown the correct injection technique by your doctor or nurse. Use a new needle for each injection and do not share the pen with another person.

If you miss a dose, follow the missed-dose instructions provided with your prescription and product information. Do not take two doses together to make up for a missed dose.

Common side effects:

• Nausea

• Vomiting

• Diarrhoea

• Constipation

• Abdominal pain

• Headache

• Dizziness

• Indigestion

• Decreased appetite

These effects are more likely when the dose is increased and may become less noticeable as the body adjusts.

Serious side effects:

• Severe or persistent abdominal pain, which may indicate pancreatitis

• Severe allergic reactions such as swelling of the face, lips, tongue or throat

• Persistent vomiting or diarrhoea that may lead to dehydration

• Gallstones or inflammation of the gallbladder

• Sudden or worsening changes in vision

• Low blood sugar, particularly when used with insulin or sulfonylureas

Seek medical attention if you develop severe or persistent symptoms.

• Use Poviztra exactly as prescribed and do not change the weekly dose yourself.

• Follow your recommended reduced-calorie diet and physical activity plan.

• Drink enough fluids, particularly if you have vomiting or diarrhoea.

• Rotate injection sites rather than repeatedly injecting into the same area.

• Use a new needle for every injection and never share your pen.

• Tell your doctor if you have diabetic retinopathy or develop changes in vision.

• Inform your doctor before surgery or a procedure involving general anaesthesia or deep sedation.

• Seek medical attention for severe or persistent abdominal pain.